• Christopher Moreau, CEO of Algernon Pharmaceuticals sat down with Brieanna McCutcheon to discuss Algernon’s unique approach to the psychedelics and health care sectors
  • Algernon Pharmaceuticals is a clinical stage pharmaceutical development company that investigates safe, already approved drugs and compounds for new disease applications
  • The company is advancing several compounds including Ifenprodil and DMT
  • Algernon is closing enrollment for a 20-patient Ifenprodil study
  • Shares of Algernon Pharmaceuticals Inc. (AGN) are currently trading at $7.99

Christopher Moreau, CEO of Algernon Pharmaceuticals sat down with Brieanna McCutcheon to discuss Algernon’s approach to the psychedelics and health care sectors.

Algernon Pharmaceuticals is a clinical-stage pharmaceutical development company. Algernon investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications.

Algernon is currently advancing a number of compounds including Ifenprodil for the treatment of chronic cough and N, N-Dimethyltryptamine, or DMT, a hallucinogenic drug for stroke treatment.

Algernon is currently closing enrollment for a 20-patient Ifenprodil study in Australia and New Zealand.

Shares of Algernon Pharmaceuticals Inc. (AGN) are currently trading at $7.99.

More From The Market Online

Quit smoking with psychedelics? A new frontier for treatment — and investors

A new Johns Hopkins study found that a single dose of psilocybin, combined with therapy, helped smokers stay cigarette free at six months.

New bladder cancer drug may sharpen radiation’s aim

Theralase Technologies proves that its Rutherrin drug holds the potential to enhance radiation against non-muscle invasive bladder cancer.

FDA grants full approval to Pfizer’s colorectal cancer treatment

The FDA granted full approval to Pfizer’s (NYSE:PFE) BRAFTOVI + cetuximab + fluorouracil based chemotherapy for adults.